Lucid Diagnostics Inc. (LUCD) Stock

Lucid Diagnostics Inc. is a pioneering medical diagnostics technology company operating at the forefront of the commercial-stage. Specializing in gastroesophageal reflux disease (GERD), also known as chronic heartburn or acid reflux, Lucid Diagnostics focuses on patients at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Central to its portfolio are innovative products like EsoGuard, a laboratory developed test for esophageal DNA analysis, and EsoCheck, an advanced device for collecting esophageal cells.

Founded in 2018 and headquartered in New York, New York, Lucid Diagnostics Inc. is committed to advancing diagnostic solutions that improve patient outcomes and enhance early detection of esophageal diseases. As a subsidiary of PAVmed Inc., the company benefits from a strong foundation and strategic support to drive innovation and expand its impact in the medical diagnostics field.

With a mission to address critical unmet needs in gastrointestinal health, Lucid Diagnostics combines cutting-edge technology with rigorous scientific research to provide healthcare professionals with reliable tools for early disease detection and management. Through its innovative approach, the company aims to transform the diagnosis and treatment landscape for patients worldwide.